Search Results for: traditional cost-effectiveness

Institute for Clinical and Economic Review Report on Voretigene Neparvovec Suggests Substantial Price Discount Needed to Meet Traditional Cost-Effectiveness Standards

–Special considerations include patient age, benefit durability, and rarity of condition–  –Report will be subject to public deliberation at January 25th Midwest CEPAC meeting– BOSTON, January 12, 2018 – The Institute for Clinical and Economic Review (ICER) today released its revised Evidence Report assessing the comparative clinical effectiveness and value of voretigene neparvovec (LuxturnaTM, Spark Therapeutics) for treatment of vision […]

Read more


Institute for Clinical and Economic Review Finds Treatments Prevent Hereditary Angioedema Attacks, but Cost-Effectiveness Uncertain and Sensitive to Frequency of Attacks

— As with all treatments for ultra-rare conditions, judgments of overall value require consideration of the broader patient benefits and contextual issues that will be discussed at the October 25 public meeting — BOSTON, October 11, 2018 – The Institute for Clinical and Economic Review (ICER) today released an Evidence Report assessing the comparative clinical effectiveness and value […]

Read more


ICER’s Assessment Finds Spinraza and Zolgensma Provide Substantial Health Benefits for People with Spinal Muscular Atrophy

–Current pricing of Spinraza would require a substantial discount to meet traditional cost-effectiveness ranges; Zolgensma’s value-based price range is between $310,000-$900,000 using standard methodology but as high as $1.5 million using alternative measures of health gain– –As with all treatments for ultra-rare conditions, judgments of overall value require consideration of contextual issues and broader benefits […]

Read more


ICER Value Assessment Framework

The ICER value framework describes the conceptual framework and set of associated methods that guide the development of ICER evidence reports.  The purpose of the value framework is to form the backbone of rigorous, transparent evidence reports that, as a basis for broader stakeholder and public engagement, will help the United States evolve toward a […]

Read more


ICER Finalizes Method Adaptations for Assessing Potential Cures and Other High-Impact Single or Short-term Therapies

— Collaborative project with NICE and CADTH leads to important adaptations for ICER’s methods including creation of optimistic and conservative benefit scenarios; new dimensions of benefits and contextual considerations for voting; and two new scenarios that display the potential impact on pricing that would result from sharing the savings of downstream cost offsets between society […]

Read more


ICER Proposes Updates to 2020 Value Assessment Framework Methods and Procedures

— Reflecting experience with current framework, benchmarking with other HTA groups, and public input, proposals include new emphasis on real-world evidence, revised approach to voting on contextual considerations, and a formal process for report updates at 12 months after initial release — — Proposals to be discussed during a webinar on September 4; Public comment […]

Read more


ICER Issues Final Report and Policy Recommendations Regarding Treatments for Duchenne Muscular Dystrophy

— Public meeting reveals tensions inherent around high-priced treatments that lack adequate evidence of efficacy — BOSTON, August 15, 2019 – The Institute for Clinical and Economic Review (ICER) today released a Final Evidence Report and Report-at-a-Glance assessing the comparative clinical effectiveness and value of the corticosteroid deflazacort (Emflaza®, PTC Therapeutics), and two exon-skipping therapies — eteplirsen […]

Read more


ICER Publishes Evidence Report on Treatments for Duchenne Muscular Dystrophy

— No price can be suggested as a fair value-based price for eteplirsen or golodirsen because no persuasive evidence yet exists to demonstrate the clinical effectiveness of either drug — — For deflazacort, discounts of at least 73% from its list price would be needed to achieve commonly cited thresholds for cost-effectiveness — — As […]

Read more


ICER Issues Final Report on Spinraza and Zolgensma, Provides Policy Recommendations Related to Pricing and Coverage of Treatments for Spinal Muscular Atrophy

— Independent appraisal committee notes family testimony in votes confirming broad benefits of both treatments; however, committee votes unanimously that price for Spinraza is too high to align fairly with these benefits, and urges fair pricing for emerging gene therapy Zolgensma to support sustainable access to innovation — BOSTON, April 3, 2019 – The Institute for Clinical […]

Read more